

## Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Bill-Axelsson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. *N Engl J Med* 2014;370:932-42. DOI: 10.1056/NEJMoa1311593

## Supplementary Appendix

Supplement to Bill-Axelson, Holmberg L, Garmo H et al. Radical prostatectomy versus watchful waiting in early prostate cancer

### Contents

Appendix author contribution	page 2
Figure S1	page 4
Table S1	page 5

## **Appendix**

*Author contributions:* As Principal Investigator, Dr. J-E. Johansson had full access to all the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis. Drs. Bill-Axelsson and Holmberg contributed equally.

*Study concept and design:* Adami, Johansson and Norlén (former principal investigator).

*Acquisition of data:* Andrén, Andersson, Bill-Axelsson, Busch, Häggman, Johansson, Nordling, Taari, Spångberg.

*Analysis and interpretation of data:* Andrén, Adami, Bill-Axelsson, Holmberg, Garmo, Johansson, Rider, Steineck.

*Drafting of the manuscript:* Adami, Bill-Axelsson, Garmo, Holmberg, Rider.

*Critical revision of the manuscript for important intellectual content:* Andrén, Andersson, Adami, Bill-Axelsson, Busch, Garmo, Holmberg, Häggman, Johansson, Nordling, Palmgren, Rider, Steineck Spångberg.

*Obtained funding:* Adami, Bill-Axelsson, Holmberg, Johansson.

*Administrative support:* Bill-Axelsson, Holmberg, Johansson, Steineck.

*Study supervision:* Johansson.

*Reference pathologists:* Busch, Nordling.

All authors agreed to publish the results.

*Ethics:* The study was approved by all appropriate ethics committees.


*Conflicts of interest:* None of the authors has any conflict of interest.

*Funding:* The Swedish Cancer Society (07 05 12 to J-E.J, 09 05 12 ABA.) and the National Institutes of Health in the United States of America (1ROI CA 108746-01A1 to G.S.). Karolinska Institutet, Distinguished Professor Award to Hans-Olov Adami (grant number Dnr: 2368/10-221) The prostate cancer foundation and Percy Falk foundation (ABA).

No funding organization had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

*Note:* We dedicate this article in memory of and gratitude to our first principal investigator, Professor Bo Johan Norlén, and our Finnish co-worker, Professor Mirja Ruutu, who both left us too early and too suddenly. We also want to express sincere gratitude to our monitor Birgitta Gobén who retired after almost twenty years of service on the SPCG-4 study. We also want to thank the following people involved in the study: The study group for recruitment and data collection – Torsten Lindeborg, Gudmundur Einarsson, Peter Ekman, Hans Wijkström, Lars Karlberg, Gunnar Hagberg, Stefan Bratell; Reference pathologists Christer Busch, Manuell de la Torre, Hans Hamberg, Anders Lindgren; Computer Support – Enayat Mavadati; Research secretary – Irene Pettersson; and the Endpoint Committee – Jan-Erik Damber, Anders Lindgren and Eberhard Varenhorst.

**Figure S1** Flow-chart: The 695 men randomly assigned in the SPCG-4 study  
 RT = radiation therapy; RP= radical prostatectomy



**Table S1. Baseline Clinical Characteristics: The 695 Men in the SPCG-4 Study by Randomization Group and Risk Group Category.**

Characteristics	All		Low risk		Intermediate risk		High risk	
	Radical	Watchful	Radical	Watchful	Radical	Watchful	Radical	Watchful
	prostatectomy (n=347)	waiting (n=348)	prostatectomy (n=118)	waiting (n=131)	prostatectomy (n=148)	waiting (n=133)	prostatectomy (n=81)	waiting (n=84)
<b>Age</b>								
< 65 years	157 (45.2)	166 (47.7)	59 (50)	65 (49.6)	63 (42.6)	65 (48.9)	35 (43.2)	36 (42.9)
≥ 65 years	190 (54.8)	182 (52.3)	59 (50)	66 (50.4)	85 (57.4)	68 (51.1)	46 (56.8)	48 (57.1)
Mean (sd), years	64.6 (5.1)	64.5 (5.0)	64.2 (4.7)	64.6 (5.0)	64.9 (5.5)	64 (4.7)	64.8 (4.9)	65.2 (5.5)
Mean PSA, ng/ml	13.5	12.3	5.8	5.2	11.5	11.4	28.5	24.6
<b>Tumor stage – no. (%)</b>								
T1b	33 (9.5)	50 (14.4)	19 (16.1)	24 (18.3)	10 (6.8)	16 (12)	4 (4.9)	10 (11.9)
T1c	43 (12.4)	38 (10.9)	14 (11.9)	15 (11.5)	17 (11.5)	14 (10.5)	12 (14.8)	9 (10.7)
T2	270 (77.8)	259 (74.4)	84 (71.2)	92 (70.2)	121 (81.8)	103 (77.4)	65 (80.2)	64 (76.2)
Unknown <sup>#</sup>	1 (0.3)	1 (0.3)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.2)
<b>WHO grade – no. (%)</b>								
1	168 (48.4)	166 (47.7)	78 (66.1)	92 (70.2)	65 (43.9)	46 (34.6)	25 (30.9)	28 (33.3)
2	178 (51.3)	182 (52.3)	39 (33.1)	39 (29.8)	83 (56.1)	87 (65.4)	56 (69.1)	56 (66.7)
Unknown	1 (0.3)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

<b>Gleason score – no. (%)</b>																
2-4	44	(12.7)	46	(13.2)	29	(24.6)	31	(23.7)	15	(10.1)	11	(8.3)	0	(0.0)	4	(4.8)
5-6	165	(47.6)	166	(47.7)	79	(66.9)	88	(67.2)	54	(36.5)	51	(38.3)	32	(39.5)	27	(32.1)
7	77	(22.2)	82	(23.6)	-	-	-	-	58	(39.2)	54	(40.6)	19	(23.5)	28	(33.3)
8-10	14	(4.0)	21	(6.0)	-	-	-	-	0	(0.0)	0	(0.0)	14	(17.3)	21	(25)
Unknown	47	(13.5)	33	(9.5)	10	(8.5)	12	(9.2)	21	(14.2)	17	(12.8)	16	(19.8)	4	(4.8)
<b>Method of detection – no. (%)</b>																
Opportunistic screening <sup>□</sup>	18	(5.2)	18	(5.2)	8	(6.8)	8	(6.1)	5	(3.4)	5	(3.8)	5	(6.2)	5	(6.0)
Coincidental <sup>§</sup>	87	(25.1)	91	(26.1)	25	(21.2)	35	(26.7)	41	(27.7)	36	(27.1)	21	(25.9)	20	(23.8)
TURP	40	(11.5)	56	(16.1)	25	(21.2)	29	(22.1)	9	(6.1)	18	(13.5)	6	(7.4)	9	(10.7)
Symptoms	152	(43.8)	138	(39.7)	46	(39.0)	43	(32.8)	70	(47.3)	59	(44.4)	36	(44.4)	36	(42.9)
Other	49	(14.1)	44	(12.6)	14	(11.9)	16	(12.2)	22	(14.9)	14	(10.5)	13	(16)	14	(16.7)
Unknown	1	(0.3)	1	(0.3)	0	(0.0)	0	(0.0)	1	(0.7)	1	(0.8)	0	(0.0)	0	(0.0)
<b>PSA level – no. (%)</b>																
<4 ng/ml	43	(12.4)	63	(18.1)	33	(28.0)	49	(37.4)	8	(5.4)	9	(6.8)	2	(2.5)	5	(6.0)
4-6.9 ng/ml	60	(17.3)	60	(17.2)	36	(30.5)	42	(32.1)	21	(14.2)	15	(11.3)	3	(3.7)	3	(3.6)
7-10 ng/ml	68	(19.6)	67	(19.3)	49	(41.5)	40	(30.5)	16	(10.8)	25	(18.8)	3	(3.7)	2	(2.4)
10.1-20 ng/ml	100	(28.8)	95	(27.3)	-	-	-	-	96	(64.9)	81	(60.9)	4	(4.9)	14	(16.7)
>20 ng/ml	69	(19.9)	60	(17.2)	-	-	-	-	-	-	-	-	69	(85.2)	60	(71.4)

Unknown	7	(2)	3	(0.9)	-	-	-	-	7	(4.7)	3	(2.3)	0	(0.0)	0	(0.0)
---------	---	-----	---	-------	---	---	---	---	---	-------	---	-------	---	-------	---	-------

<sup>#</sup>Diagnosis was made by cytologic examination only in 55 patients; a biopsy specimen could not be retrieved in 24 patients.

<sup>□</sup>PSA levels assayed due to opportunistic screening in asymptomatic men

<sup>§</sup>Coincidental detection due to other symptoms for which rectal examination was carried out.

*Low risk:* PSA < 10 and either Gleason score < 7 or WHO grade 1 for those with only cytology diagnosis.

*High risk:* PSA ≥ 20 or Gleason score > 7.

*Intermediate risk:* all that did not fulfill the criteria for low or high risk.